Treating PTSD Topically & Directly To The Brain? Psychedelics Delivery Company Poised For Major Breakthrough

Psycheceutical Bioscience, Inc (OTCPK: BWVI) is a cutting-edge biotech startup that developed a topical drug delivery system called NeuroDirect, a system that can be used to deliver psychedelic drugs directly to the brain, avoiding the traditional “high” and side effects. The company is currently conducting trials in Australia for the treatment of PTSD and complex regional pain syndrome. Earlier this month, Psycheceutical announced the completion of dosing the first cohort of subjects in a Phase I clinical trial of its topical ketamine formulation for PTSD. So Far, So Good If successful, NeuroDirect could have applications for a wide range of neuro-related conditions, including Parkinson’s, drug addiction and traumatic brain injury. Backed by Shark Tank investor Kevin Harrington and led by Mike Zapolin, AKA Zappy, a former Wall Street VP, chief visionary officer and advisor to Psycheceutical. Zappolin, who spoke at the April Benzinga Psychedelics Capital Conference in Miami explained that the company has also received a number of patents for topical back-of-the-neck drug delivery. This approach could ... Full story available on Benzinga.com ketamine psychedelic ptsd psychedelics capital

Read More